AbbVie Acquires Apogee Therapeutics for $10.9 Billion, Expanding Immunology Pipeline (ABBV)
What happened
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics, a move aimed at reinforcing its position in immunology following the continued erosion of Humira revenue. Apogee's pipeline includes investigational antibody therapies targeting atopic dermatitis and other inflammatory conditions. The deal adds to AbbVie's existing immunology portfolio, which already includes Skyrizi and Rinvoq. AbbVie carries Dividend King status, having raised its dividend for over 50 consecutive years.
The QL Read
With breadth deeply compressed at 17% advancing and ABBV's composite signal at a neutral 46/100, this deal lands in a risk-off tape that offers little near-term momentum lift. Watch for analyst price-target revisions as the first signal catalyst.
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.